Concepedia
Statistics
Publications
5
Citations
207
H-Index
Active since
2001
Affiliations
Research Triangle Park Foundation(Current)
GlaxoSmithKline (United States)
GlaxoSmithKline (United Kingdom)
GlaxoSmithKline (Canada)
R. O’Connor‐Semmes is an author at Research Triangle Park Foundation specializing in pharmacology, clinical pharmacology, and pharmacy.
Publications per year
2001–2014
Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
Robert L. Dobbins, R. O’Connor‐Semmes, Anita Kapur et al. · Diabetes Obesity and Metabolism · 2011 · 76 citations
Pharmacy, Pharmacology, Pharmacotherapy +17
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety
R. O’Connor‐Semmes, Jian Lin, Rebecca J. Hodge et al. · Clinical Pharmacology & Therapeutics · 2014 · 49 citations
Pharmacy, Pharmacokinetics, Pharmacology +17
Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes
A.P. Sykes, R. O’Connor‐Semmes, Robert L. Dobbins et al. · Diabetes Obesity and Metabolism · 2014 · 40 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes
A.P. Sykes, George L. Kemp, Robert L. Dobbins et al. · Diabetes Obesity and Metabolism · 2014 · 32 citations
Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people
R. O’Connor‐Semmes · Clinical Pharmacology & Therapeutics · 2001 · 10 citations
Pharmacy, Clinical Pharmacokinetics, Pharmacology +15
1–5 of 5